Growth is expected to be supported by ENHERTU's continued expansion. Profit attributable to owners of the company for FY2024 was revised upward by ¥15 billion to ¥240 billion, driven by improved ...

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

Top-line data from the study showed that people treated with amycretin experienced a weight loss of 9.7% for the 1.25 mg dose over 20 weeks ... AZN & Daiichi’s Enhertu for Expanded Breast ...

Enhertu was discovered by Daiichi Sankyo and is being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. HER2 is a receptor protein that accelerates the growth of cancer cells.

1. Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for Enhertu. Roche. News release. January 31 ...

NEW YORK – Roche announced on Friday that its Pathway Anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody has received a label expansion from the US Food and Drug Administration as a companion ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

As­traZeneca and Dai­ichi Sankyo’s an­ti­body-drug con­ju­gate En­her­tu is now ap­proved to treat a new sub­set of breast can­cer pa­tients with very low lev­els of HER2 … ...

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...